U of A researcher to work with Northwest Territories communities to promote HPV vaccination, improve COVID-19 vaccination experience

Five-year project to develop culturally appropriate program is among 19 U of A projects to receive new funding from Canadian Institutes of Health Research.

210312-2017_sharma_sangita-0503-main-16x9-3600px.jpg

U of A researcher Sangita Sharma is leading a project working with communities in the Northwest Territories to co-create a culturally appropriate program encouraging more people to get vaccinated against HPV. The team will also gauge people's attitudes and experiences related to COVID-19 vaccines. (Photo: Faculty of Medicine & Dentistry)

A University of Alberta researcher will consult with two Indigenous communities in the Northwest Territories to co-create a culturally appropriate promotion program for the human papillomavirus (HPV) vaccine.

HPV is the most common sexually transmitted infection and the main cause of cervical cancer worldwide, but it is preventable with a vaccine for females aged nine to 45 years and males aged nine to 26. The vaccination rate in Northwest Territories is 55 per cent compared with up to 92 per cent in other parts of the country. 

“We’re aiming to develop a community-based program that addresses the communities’ concerns for HPV and ultimately reduces HPV-related cancers,” said Sangita Sharma, University of Alberta Centennial Professor in the Faculty of Medicine & Dentistry and lead of the Indigenous and Global Health Research Group

The Canadian Institutes of Health Research (CIHR) announced today that Sharma and her partners have been granted $2.1 million to investigate and improve the utilization of HPV vaccination. The initiative is one of 19 U of A projects receiving a total of $13.7 million in funding from CIHR.

The team will also capture experiences with the COVID-19 vaccine and examine attitudes toward COVID-19 vaccination. The Northwest Territories government is currently offering the Moderna vaccine to anyone over the age of 18.

Tapping into the wisdom of the community

The project team will work with one small, remote community and another medium-sized, semi-remote community. Community conversations will include Inuvialuit, First Nations and Métis peoples. The project will take five years and will be guided by community advisory boards that include Indigenous community members, leaders and Elders.

“We’re hoping our consultations will take place through on-the-land activities such as fishing, hunting, beading and hide tanning—while the youth are learning from grandparents and parents, from the Elders, so we get the whole community’s perspective,” said Sharma, who also holds the Alberta Health Services Chair in Indigenous Health.

The team will use an approach to research known as “Two-Eyed Seeing,” which Sharma explained incorporates the strengths of Indigenous knowledge, wisdom and ways of knowing with the strengths of western knowledge and ways of knowing.

This project builds on Sharma’s previous research on attitudes toward cancer and cancer screening in Indigenous communities, which led to the development of a series of educational videos

Sharma’s partners on the project include the two northern communities, the community advisory boards, the Hotıì ts'eeda research unit and Northwest Territories Health and Social Services, as well as Fariba Kolahdooz, executive director of U of A’s Indigenous and Global Health Research Group; Gina Ogilvie and Carolyn Gotay of the University of British Columbia; and Donna Kurtz of UBC Okanagan. 

Other U of A projects receiving CIHR funding

Jason Acker,
Faculty of Medicine & Dentistry

Enabling liver cryopreservation by controlling ice recrystallization with small molecule inhibitors

$600,524
Lauren Beaupré, Allyson Jones,
Faculty of Rehabilitation Medicine

Preoperative e-health to prepare for elective total joint replacement surgery: The Prep@Home randomized feasibility trial

$100,000
Fred Colbourne,
Faculty of Science

Brain cell volume reduction in animal models and people with intracerebral hemorrhagic stroke

$807,075
Greta Cummings, Carole Estabrooks,
Faculty of Nursing

How missed care occurs in nursing homes: A qualitative study of care aides’ perspectives

$100,000
Shokrollah Elahi,
Faculty of Medicine & Dentistry

Deciphering immune responses in COVID-19 patients to identify immune correlates of protection and susceptibility for targeted therapeutics

$1,071,000
Carole Estabrooks, Greta Cummings,
Faculty of Nursing

The impact of the COVID-19 pandemic on long-term care home staff and residents

$756,890
Carole Estabrooks,
Faculty of Nursing

Experiences of care aides in long-term care with residents having psychological trauma

$195,076
Karim Fouad,
Faculty of Rehabilitation Medicine

Role of inflammation in recovery after spinal cord injury

$956,250
René Jacobs,
Faculty of Agricultural, Life and Environmental Sciences

Dietary ethanolamine and phosphoethanolamine phosphorylase as novel modulators of liver health

$100,000
Vera Mazurak,
Faculty of Agricultural, Life and Environmental Sciences 

Feeding EPA and DHA to improve clinical symptoms associated with COVID-19 infection

$344,250
Allan Murray,
Faculty of Medicine & Dentistry

Repair in transplant vasculopathy

$807,075
Vivian Mushahwar,
Faculty of Medicine & Dentistry

Spinal neuromodulation for restoring function after neural injury or disease

$1,162,800
Gavin Oudit,
Faculty of Medicine & Dentistry

Pathogenesis of COVID-19 mediated cardiovascular complications: Therapeutic applications

$875,925
Simonetta Sipione,
Faculty of Medicine & Dentistry

The role of glycosphingolipids in the secretion and clearance of extracellular vesicles in brain health and disease

$1,040,400
Hasan Uludag,
Faculty of Engineering

Synthetic biomaterials to package and deliver siRNA nanoparticles in order to curb uncontrolled growth of leukemic cells

$757,350
Harissios Vliagoftis,
Faculty of Medicine & Dentistry

Proteinase-activated receptor-2 agonists for mucosal vaccination

$998,325
Toshifumi Yokota,
Faculty of Medicine & Dentistry

Development of antisense oligonucleotide-based therapy for facioscapulohumeral muscular dystrophy

$865,800